NO20064794L - Anvendelse av anti-alfa5beta1-antistoffer for inhibering av kreftcelleproliferasjon - Google Patents

Anvendelse av anti-alfa5beta1-antistoffer for inhibering av kreftcelleproliferasjon

Info

Publication number
NO20064794L
NO20064794L NO20064794A NO20064794A NO20064794L NO 20064794 L NO20064794 L NO 20064794L NO 20064794 A NO20064794 A NO 20064794A NO 20064794 A NO20064794 A NO 20064794A NO 20064794 L NO20064794 L NO 20064794L
Authority
NO
Norway
Prior art keywords
cancer
antibodies
methods
cancer cell
cell proliferation
Prior art date
Application number
NO20064794A
Other languages
English (en)
Norwegian (no)
Inventor
Vanitha Ramakrishnan
Vinay Bhaskar
Sun Ho
Richard Murray
Debbie Law
Original Assignee
Pdl Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pdl Biopharma Inc filed Critical Pdl Biopharma Inc
Publication of NO20064794L publication Critical patent/NO20064794L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
NO20064794A 2004-03-24 2006-10-23 Anvendelse av anti-alfa5beta1-antistoffer for inhibering av kreftcelleproliferasjon NO20064794L (no)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US55642104P 2004-03-24 2004-03-24
US55642204P 2004-03-24 2004-03-24
US62504904P 2004-11-03 2004-11-03
US65109805P 2005-02-07 2005-02-07
US65751405P 2005-02-28 2005-02-28
PCT/US2005/009939 WO2005092073A2 (en) 2004-03-24 2005-03-24 Use of anti-alpha5beta1 antibodies to inhibit cancer cell proliferation

Publications (1)

Publication Number Publication Date
NO20064794L true NO20064794L (no) 2006-10-23

Family

ID=35056776

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20064794A NO20064794L (no) 2004-03-24 2006-10-23 Anvendelse av anti-alfa5beta1-antistoffer for inhibering av kreftcelleproliferasjon

Country Status (14)

Country Link
US (2) US7662384B2 (de)
EP (1) EP1755659B1 (de)
JP (1) JP4857259B2 (de)
KR (1) KR20070009637A (de)
AT (1) ATE531388T1 (de)
AU (1) AU2005226736B2 (de)
BR (1) BRPI0509177A (de)
CA (1) CA2560508A1 (de)
DK (1) DK1755659T3 (de)
ES (1) ES2376556T3 (de)
IL (1) IL178042A (de)
NO (1) NO20064794L (de)
NZ (1) NZ549893A (de)
WO (1) WO2005092073A2 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090220508A1 (en) 2006-03-15 2009-09-03 Alexion Pharmaceuticals, Inc. Treatment Of Paroxysmal Nocturnal Hemoglobinuria Patients By An Inhibitor Of Complement
NZ615012A (en) * 2006-03-21 2015-11-27 Genentech Inc Combinatorial therapy involving alpha5beta1 antagonists
WO2007114851A1 (en) * 2006-04-04 2007-10-11 The Board Of Trustees Of The University Of Illinois Methods and compositions to induce cell death of invasive tumors
EA200802348A1 (ru) * 2006-05-24 2009-08-28 Байер Шеринг Фарма Акциенгезельшафт ЧЕЛОВЕЧЕСКИЙ ВЫСОКОАФФИННЫЙ И ГУМАНИЗИРОВАННЫЙ АНТИ-α5β1 ИНТЕГРИН С ФУНКЦИЕЙ БЛОКИРУЮЩЕГО АНТИТЕЛА С ОСЛАБЛЕННОЙ ИММУНОГЕННОСТЬЮ
WO2008061377A1 (en) * 2006-11-22 2008-05-29 Centre Hospitalier De L'universite De Montreal Novel receptor for cd40l and uses thereof
WO2009018226A2 (en) * 2007-07-27 2009-02-05 Facet Biotech Corporation Pharmaceutical combinations comprising a tyrosine kinase inhibitor and an antibody against integrin alpha 1 beta 5 (cd49e)
MY151191A (en) * 2007-09-26 2014-04-30 Genentech Inc Novel antibodies
EP2650017A3 (de) * 2008-02-05 2014-01-22 Bristol-Myers Squibb Company Alpha-5-beta-1-Antikörper und deren Verwendungen
CA2748158A1 (en) 2008-12-23 2010-07-01 Astrazeneca Ab Targeted binding agents directed to .alpha.5.beta.1 and uses thereof
NZ594343A (en) * 2009-03-25 2013-10-25 Genentech Inc Novel anti-alpha5beta1 antibodies and uses thereof
US20110319335A1 (en) 2010-06-23 2011-12-29 Xiaodong Feng Combined administration of integrin receptor antagonists for anti-angiogenic therapy
CN107233569B (zh) 2011-10-25 2021-08-31 普罗西纳生物科学有限公司 抗体制剂和方法
US8946159B2 (en) * 2011-12-22 2015-02-03 California Northstate College Of Pharmacy, Llc Administration of an antagonist of α5β1 for anti-angiogenesis and cancer treatment
NO2760138T3 (de) 2012-10-01 2018-08-04
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
JP7382232B2 (ja) 2017-05-02 2023-11-16 メルク・シャープ・アンド・ドーム・エルエルシー 抗ｌａｇ３抗体の製剤および抗ｌａｇ３抗体と抗ｐｄ－１抗体との共製剤
WO2020081408A1 (en) 2018-10-18 2020-04-23 Merck Sharp & Dohme Corp. Formulations of anti-rsv antibodies and methods of use thereof
MX2021004928A (es) 2018-10-31 2021-06-08 Merck Sharp & Dohme Llc Cristales de anticuerpo anti-pd-1 humano y metodos de uso de los mismos.
EP3876990A4 (de) 2018-11-07 2023-09-06 Merck Sharp & Dohme LLC Co-formulierungen von anti-lag3 -antikörpern und anti-pd-1-antikörpern
WO2025106725A2 (en) * 2023-11-15 2025-05-22 Morphic Therapeutic, Inc. HUMAN ANTI-α5β1 ANTIBODIES AND USES THEREOF
WO2025106724A2 (en) * 2023-11-15 2025-05-22 Morphic Therapeutic, Inc. USE OF ANTI-α5β1 ANTIBODIES IN THE TREATMENT OF PULMONARY HYPERTENSION AND HEART FAILURE

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704366A (en) * 1984-06-22 1987-11-03 Bio-Rad Laboratories, Inc. Process for binding IgG to protein A
JPS61134325A (ja) * 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4801687A (en) * 1986-10-27 1989-01-31 Bioprobe International, Inc. Monoclonal antibody purification process using protein A
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2082160C (en) * 1991-03-06 2003-05-06 Mary M. Bendig Humanised and chimeric monoclonal antibodies
AU669124B2 (en) * 1991-09-18 1996-05-30 Kyowa Hakko Kirin Co., Ltd. Process for producing humanized chimera antibody
GB9125979D0 (en) * 1991-12-06 1992-02-05 Wellcome Found Antibody
CA2130436C (en) * 1992-02-19 2001-04-10 John S. Abrams Cloning and expression of humanized monoclonal antibodies against human interleukin-4
US5639641A (en) * 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
ATE250138T1 (de) 1992-10-29 2003-10-15 Univ Australian Angiogenese-inhibierende antikörper
US5536814A (en) * 1993-09-27 1996-07-16 La Jolla Cancer Research Foundation Integrin-binding peptides
US5981478A (en) 1993-11-24 1999-11-09 La Jolla Cancer Research Foundation Integrin-binding peptides
EP0745134A1 (de) 1994-02-22 1996-12-04 Danafarber Cancer Institute Nukleinsäureverabreichungs-system, verfahren zur dessen synthese und seine verwendungen
DE69516351T2 (de) * 1994-09-21 2000-12-07 Matsushita Electric Industrial Co., Ltd. Sekundäre Lithium Feststoffbatterie
US5705154A (en) * 1995-03-08 1998-01-06 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
WO1997033887A1 (en) 1996-03-15 1997-09-18 Du Pont Pharmaceuticals Company Spirocycle integrin inhibitors
US5922676A (en) * 1996-09-20 1999-07-13 The Burnham Institute Methods of inhibiting cancer by using superfibronectin
US5846536A (en) 1996-10-04 1998-12-08 The Regents Of The University Of California Restoration of normal phenotype in cancer cells
WO1998032771A1 (en) 1997-01-29 1998-07-30 Toray Industries, Inc. Chimeric proteins, heterodimer complexes thereof and substitute for platelet
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
AU2444899A (en) * 1998-01-22 1999-08-09 Astrazeneca Ab Pharmaceutical formulation comprising an antibody and a citrate buffer
EP1075543A2 (de) 1998-04-27 2001-02-14 Sidney Kimmel Cancer Center Zielnukleinsäure mit reduzierter komplexität und verfahren zu ihrer verwendung
US6852318B1 (en) * 1998-05-08 2005-02-08 The Regents Of The University Of California Methods for detecting and inhibiting angiogenesis
WO1999058139A2 (en) * 1998-05-08 1999-11-18 The Regents Of The University Of California Methods for detecting and inhibiting angiogenesis
JP2003517816A (ja) 1999-08-11 2003-06-03 イオス バイオテクノロジー， インコーポレイテッド 新脈管形成の診断の新規方法、新脈管形成調節因子についてのスクリーニングの組成物および方法
CA2397194C (en) 2000-01-20 2011-05-17 Mark E. Duggan Alpha v integrin receptor antagonists
CA2397665A1 (en) 2000-01-24 2001-07-26 Merck & Co., Inc. Alpha v integrin receptor antagonists
US7740841B1 (en) * 2000-01-28 2010-06-22 Sunnybrook Health Science Center Therapeutic method for reducing angiogenesis
US20040259152A1 (en) * 2000-02-22 2004-12-23 Richard Murray Novel methods of diagnosing and screening for modulators of tissue remodeling and treating related diseases
CA2438030A1 (en) 2001-02-14 2002-10-10 Protein Design Labs Methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators
JP4741242B2 (ja) * 2002-11-26 2011-08-03 アボット バイオセラピューティクス コーポレイション 新脈管形成を調節するα５β１インテグリンへのキメラ及びヒト化抗体
US7276589B2 (en) * 2002-11-26 2007-10-02 Pdl Biopharma, Inc. Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis
JP2007524605A (ja) * 2003-04-03 2007-08-30 ピーディーエル バイオファーマ，インコーポレイティド インテグリンα５β１のインヒビターおよび組織顆粒化の制御のためのそれらの使用
CN1816356A (zh) 2003-05-14 2006-08-09 免疫原公司 药物缀合物组合物

Also Published As

Publication number Publication date
US20100291111A1 (en) 2010-11-18
CA2560508A1 (en) 2005-10-06
JP2007530584A (ja) 2007-11-01
WO2005092073A2 (en) 2005-10-06
ATE531388T1 (de) 2011-11-15
JP4857259B2 (ja) 2012-01-18
AU2005226736B2 (en) 2009-11-26
NZ549893A (en) 2010-05-28
US7662384B2 (en) 2010-02-16
EP1755659A2 (de) 2007-02-28
HK1101348A1 (en) 2007-10-18
ES2376556T3 (es) 2012-03-14
AU2005226736A1 (en) 2005-10-06
EP1755659B1 (de) 2011-11-02
IL178042A0 (en) 2006-12-31
EP1755659A4 (de) 2008-08-20
IL178042A (en) 2011-05-31
DK1755659T3 (da) 2012-02-27
WO2005092073A3 (en) 2006-08-10
BRPI0509177A (pt) 2007-09-18
KR20070009637A (ko) 2007-01-18
US20050260210A1 (en) 2005-11-24

Similar Documents

Publication Publication Date Title
NO20064794L (no) Anvendelse av anti-alfa5beta1-antistoffer for inhibering av kreftcelleproliferasjon
EA200801853A1 (ru) Пептиды, эффективные в лечении опухолей и других заболеваний, требующих удаления или разрушения клеток
DE602005027617D1 (de) Radiotherapiebehandlungsüberwachung unter einsatz von ultraschall
WO2004113571A3 (en) Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
MX2009006779A (es) Antagonistas especificos para terapia con adyuvantes y neo-adyuvantes y el tratamiento de tumores en etapa temprana.
NZ626867A (en) Compositions and methods for the treatment of infections and tumors
EA200701094A1 (ru) Усовершенствованное лечение рака с применением агонистов tlr3
WO2004064727A3 (en) Method of cancer treatment using hdac inhibitors
DE60027768D1 (de) Behandlung von metastatischer krankheit
CY1114006T1 (el) Τοπικα σκευασματα συνενζυμου q10 και μεθοδοι χρησης
CY1112739T1 (el) Αντισωματα και ανοσοσυζευγματα αντι-cd79β και μεθοδοι χρησης
EA201890957A1 (ru) Комбинированная терапия для лечения злокачественных опухолей
WO2020107002A3 (en) Methods for expansion of natural killer (nk) cell subset and related compositions and methods
EP1708752A4 (de) Therapeutisches krebsmittel mit polymergebundenem antikörper
DK1680141T3 (da) Fremgangsmåder til terapi til faste tumorer der udtrykker CD40-celleoverfladeantigenet
DE602004027992D1 (de) In metastatischen menschlichen tumorzellen exprimiertes glycoproteinantigen sima135
DE602005023488D1 (de) Tumorassoziierte antigenprofile in der krebsdiagnostik und immuntherapie
EP1605847A4 (de) Gegen antikörper gerichtete photodynamische therapie
MX2019015194A (es) Composiciones y métodos para terapia de cáncer con virus de dengue y células dendríticas.
TW200626900A (en) Wnt proteins and detection and treatment of cancer
DE60038624D1 (de) Methoden zur behandlung von festen tumoren und metastasen mit gentherapie
ATE512146T1 (de) Phenylharnstoffderivate als hemmstoffe von tyrosinkinasen zur behandlung von tumorerkrankungen
DK1185279T3 (da) Midler til behandling af maligne sygdomme ved anvendelse af proteinet YB-1
IS2254B (is) Meðhöndlun á risaeitlingasarkmeini með tálmum viðeitilfrumueiturslóðinni
EA202192964A1 (ru) Комбинированная терапия

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application